Suppression of kidney fibrosis by cGMP-dependent protein kinase I
BMC Pharmacology and Toxicology volume 14, Article number: P61 (2013)
cGMP is synthesized via nitric oxide- or natriuretic peptide-stimulated guanylyl cyclases and exhibits pleiotropic regulatory functions also in the kidney. Both isoforms of cGKI (α, β) have been detected in arterioles, mesangium and within the cortical interstitium. In contrast to cGKIα, the β-isoform was not detected in the juxtaglomerular apparatus and in medullary fibroblasts.
The aim of this study was to examine the function of cGKI in the renal interstitium, emphasizing a functional differentiation of both isoforms. Interstitium fibroblasts play a prominent role in interstitial fibrosis. Accordingly, cGKI may also be involved in this pathophysiological process.
Kidney fibrosis was induced by unilateral ureter obstruction (UUO). We treated αSM-rescue (expressing cGKIα only in smooth muscle under the control of the SM22 promotor with a cGKI-KO background), cGKI-KO mice (expressing no cGKI) and wt mice with YC-1 (sGC stimulator) which increases cGMP concentration.
Administration of YC-1 showed significantly antifibrotic effects in wt-, but not in αSM-rescue- and cGKI-KO mice, especially regarding the fibrosis marker Col1a1, TGFβ and fibronectin. Thereby cGKIα was activated by YC-1 which phosphorylates RhoA and inhibits in turn the profibrotic RhoA/ROCK pathway.
Our results indicate that cGMP/cGKIα acts via RhoA/ROCK, as an important suppressor of kidney fibrosis.
This work was supported by grants from the DFG SFB 699.
About this article
Cite this article
Schinner, E., Schramm, A., Kees, F. et al. Suppression of kidney fibrosis by cGMP-dependent protein kinase I. BMC Pharmacol Toxicol 14 (Suppl 1), P61 (2013). https://doi.org/10.1186/2050-6511-14-S1-P61